Advertisement
ARVN vs FHTX
Which Stock Would AI Choose? Arvinas, Inc. (ARVN) vs. Foghorn Therapeutics, Inc. (FHTX) Stock Comparison
Key Takeaways
- Both ARVN and FHTX are clinical-stage biotechnology companies that have faced sharp, catalyst-driven sell-offs in recent months, making this a comparison of two high-risk, early-stage oncology franchises.
- ARVN is a leader in targeted protein degradation (PROTAC), while FHTX focuses on the chromatin regulatory system, giving the two companies distinct scientific platforms and risk profiles.
- Recent clinical setbacks have weighed on both stocks: Arvinas' lead breast-cancer candidate failed to meet its primary goal in a key trial, while Foghorn discontinued its lead cancer program after Phase 1 efficacy fell short.
- Arvinas retains a larger market capitalization, a broader pipeline, and an established partnership with Pfizer, whereas Foghorn has shifted to a wholly owned, largely preclinical pipeline following the end of its Eli Lilly collaboration.
- Relative performance has diverged modestly: both stocks are down sharply year-to-date, but Arvinas has shown more resilience and holds a stronger consensus analyst rating than Foghorn.
- For additional detail on each company's developments and intraday moves, explore the ARVN Major News and ARVN Today's Price Move pages, along with the FHTX Major News and FHTX Today's Price Move pages.
- To see how automated systems are currently positioned across the market, explore the curated Trending AI Robots.
Introduction
Investors evaluating speculative biotechnology names frequently weigh a company's scientific platform, clinical milestones, and financial runway against its share-price volatility. This stock comparison examines ARVN and FHTX, two oncology-focused developers that have both experienced significant catalyst-driven declines in recent months. While neither company currently generates meaningful product revenue, their distinct approaches to treating cancer — protein degradation versus chromatin regulation — create different growth drivers and risk factors. This analysis is most relevant for traders and investors comfortable with binary, clinical-trial-driven outcomes and for those seeking to understand how market positioning, pipeline depth, and partnership stability distinguish two similarly volatile names.
ARVN Overview and Recent Performance
Arvinas, Inc. is a clinical-stage biotechnology company that pioneered PROTAC (proteolysis-targeting chimera) technology, a method of degrading disease-causing proteins rather than simply inhibiting them. Its most advanced program, vepdegestrant (developed with Pfizer), targets estrogen-receptor-positive breast cancer. In recent months, Arvinas' stock came under heavy pressure after the VERITAC-2 trial's intent-to-treat (ITT) population failed to show a significant benefit over standard therapy, prompting a sharp sell-off and a search for a third-party commercialization partner. The company has since reported encouraging early data from ARV-102, an investigational PROTAC degrader targeting LRRK2 (leucine-rich repeat kinase 2), in neurological disease. Financial results have been uneven, with revenue fluctuating due to milestone and collaboration payments. Arvinas holds a larger cash base and a broader pipeline than many peers, but near-term catalysts remain dependent on clinical readouts and partnership execution.
FHTX Overview and Recent Performance
Foghorn Therapeutics, Inc. is a clinical-stage biotechnology company focused on the chromatin regulatory system, using its "Gene Traffic Control" platform to target proteins that control gene expression in cancer. In recent weeks, Foghorn underwent a major strategic reset: after reviewing Phase 1 data, the company and collaborator Eli Lilly discontinued FHD-909, a first-in-class SMARCA2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 2) inhibitor, citing insufficient clinical efficacy. The partnership's end triggered a roughly 40% workforce reduction and a pivot to wholly owned, largely preclinical programs, including selective EP300 and CBP degraders and an oral immunology program. The restructuring is expected to extend the company's cash runway into the second half of 2029. Foghorn's shares fell sharply to multi-year lows, and several analysts downgraded the stock while cutting price targets, though some maintained positive ratings based on remaining pipeline optionality.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems designed for current market conditions. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and target universe. Rather than listing every available bot, the Trending section surfaces those best suited to the prevailing environment, helping traders identify systems whose recent behavior aligns with today's volatility and momentum patterns. This curation can be particularly useful for investors monitoring event-driven names like ARVN and FHTX, where price action shifts rapidly on clinical and partnership news. Explore the Trending AI Robots page to review the currently featured systems.
Head-to-Head Comparison
The clearest contrast between these two names lies in pipeline maturity and partnership stability. ARVN retains an active collaboration with Pfizer and a lead program that, while clinically challenged, remains in late-stage development, giving it a more substantial base of value and a larger market capitalization. By contrast, FHTX has effectively reset to a preclinical pipeline after losing its flagship partnered asset, increasing its reliance on future clinical validation and potential new partnerships. In terms of recent momentum, both stocks have suffered steep year-to-date declines, but Arvinas' loss has been comparatively shallower and its analyst consensus more favorable. Risk factors also differ: Arvinas faces competitive pressure in breast cancer and commercialization uncertainty, while Foghorn faces funding and execution risk tied to advancing early-stage programs toward human trials. Sector exposure is similar — both are small-cap oncology biotechs — but their scientific platforms and catalyst timelines diverge meaningfully.
Tickeron AI Verdict
Based on observable factors such as trend consistency, pipeline depth, partnership stability, and relative market positioning, Tickeron's AI would likely favor ARVN over FHTX in the current environment. Arvinas maintains a more diversified clinical pipeline, a larger cash position, and an established partnership with Pfizer, which generally supports greater stability and a more favorable consensus outlook despite recent setbacks. Foghorn's wholly owned pipeline offers optionality but introduces longer timelines and higher uncertainty. This assessment is probabilistic rather than definitive: both stocks remain highly volatile, and any single clinical readout or partnership announcement could materially alter their relative positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and FHTX is a Buy.
ARVN in +7.96% Uptrend, growing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 23 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.498). P/E Ratio (21.367) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FHTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FHTX turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 32 of 35 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FHTX's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHTX as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.370) is normal, around the industry mean (3.498). P/E Ratio (-1.889) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARVN | FHTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 83 | 100 | |
PRICE GROWTH RATING 1..100 | 77 | 65 | |
P/E GROWTH RATING 1..100 | 71 | 8 | |
SEASONALITY SCORE 1..100 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FHTX's Valuation (23) in the null industry is somewhat better than the same rating for ARVN (86) in the Biotechnology industry. This means that FHTX’s stock grew somewhat faster than ARVN’s over the last 12 months.
FHTX's Profit vs Risk Rating (100) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that FHTX’s stock grew similarly to ARVN’s over the last 12 months.
ARVN's SMR Rating (83) in the Biotechnology industry is in the same range as FHTX (100) in the null industry. This means that ARVN’s stock grew similarly to FHTX’s over the last 12 months.
FHTX's Price Growth Rating (65) in the null industry is in the same range as ARVN (77) in the Biotechnology industry. This means that FHTX’s stock grew similarly to ARVN’s over the last 12 months.
FHTX's P/E Growth Rating (8) in the null industry is somewhat better than the same rating for ARVN (71) in the Biotechnology industry. This means that FHTX’s stock grew somewhat faster than ARVN’s over the last 12 months.
| ARVN | FHTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 80% | 22 days ago 86% |
| Declines ODDS (%) | 6 days ago 81% | 6 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARVN’s FA Score shows that 0 FA rating(s) are green while FHTX’s FA Score has 2 green FA rating(s).
- ARVN’s FA Score: 0 green, 5 red.
- FHTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARVN’s TA Score shows that 4 TA indicator(s) are bullish while FHTX’s TA Score has 5 bullish TA indicator(s).
- ARVN’s TA Score: 4 bullish, 4 bearish.
- FHTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
ARVN (@Biotechnology) experienced а -2.40% price change this week, while FHTX (@Biotechnology) price change was -10.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ARVN is expected to report earnings on Mar 01, 2027.
FHTX is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with OLMA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then OLMA could also see price increases.
| Ticker / NAME | Correlation To ARVN | 1D Price Change % | ||
|---|---|---|---|---|
| ARVN | 100% | +2.37% | ||
| OLMA - ARVN | 48% Loosely correlated | -1.22% | ||
| BCYC - ARVN | 47% Loosely correlated | -2.12% | ||
| AXON - ARVN | 46% Loosely correlated | -0.21% | ||
| VCYT - ARVN | 46% Loosely correlated | -7.18% | ||
| STOK - ARVN | 46% Loosely correlated | -1.80% | ||
More | ||||
FHTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with ARVN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To FHTX | 1D Price Change % | ||
|---|---|---|---|---|
| FHTX | 100% | -6.86% | ||
| ARVN - FHTX | 42% Loosely correlated | +2.37% | ||
| IMTX - FHTX | 39% Loosely correlated | -0.16% | ||
| IMVT - FHTX | 39% Loosely correlated | +1.59% | ||
| DNLI - FHTX | 38% Loosely correlated | -2.36% | ||
| AXON - FHTX | 38% Loosely correlated | -0.21% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BFEW | 21.91 | N/A | N/A |
| FT Vest Laddered U.S. Equity Equal Weight Buffer ETF (BFEW) | |||
| VSHY | 21.38 | -0.05 | -0.25% |
| Virtus Newfleet Short Duration High Yield Bond ETF (VSHY) | |||
| DMAY | 47.55 | -0.14 | -0.29% |
| FT Vest U.S. Equity Deep Buffer ETF - May (DMAY) | |||
| JEDI | 21.36 | -0.27 | -1.25% |
| Defiance Drone and Modern Warfare ETF (JEDI) | |||
| BUG | 44.88 | -0.68 | -1.49% |
| Global X Cybersecurity ETF (BUG) | |||